Reacción a "CAR-T therapy tested to treat childhood brain tumours considered incurable"

The work is of high quality, with a careful experimental design and based on very solid preclinical results from the promoter group. Important data on the cell production process as well as on the toxicity and safety profile after intravenous and intracerebral infusion are analysed and obtained.

The study reinforces previously published data on the enormous potential of adoptive cell therapies based on ‘T-lymphocyte redirection’, in particular CAR-T cells, for the treatment of brain tumours. The results represent a real ‘accolade’ for this immunotherapy in terms of safety and efficacy, as it documents a case of complete remission in a patient with diffuse midline glioma, which is an incurable pathology. This study, along with others previously published, demonstrates that this type of adoptive cellular immunotherapies will become the gold standard treatment for brain tumours in the short term, and paves the way for future evolutions of this type of therapy to improve its efficacy.

[In terms of limitations] The observation period in the regressed patient is still too short to draw definitive conclusions. In addition, it is essential to deepen the immunological aspects of the response to accurately determine the persistence and location of CAR-T cells, as well as the type or nature of the induced immune response. This will be key in order to be able to implement therapy and increase response rates.